Table 1.
Microvesicles | Exosomes | Apoptotic bodies | References | |
---|---|---|---|---|
Size (nm) | 100–1000 | 30–200 | 1000–5000 | (Akers et al., 2013, van Niel et al., 2018, Al-Nedawi et al., 2009, Théry et al., 2009, Minciacchi et al., 2015) |
Morphological appearance | Various shapes | Cup shaped | heterogeneous | (Mathivanan et al., 2010, Théry et al., 2009, Skog et al., 2008) |
Protein components | Death receptors such as CD40 ligand, Cell adhesion (integrins, selectins), |
Tetraspanins (CD63, CD9 CD82, CD81), Multivesicular bodies (TSG101, ALIX) | Transcription factors and histones | (Al-Nedawi et al., 2009) |
Lipid composition | Cholesterol, High phosphatidylserine exposure | Cholesterol, sphingomyelin, lipid rafts, ceramide, low phosphatidylserine exposure | Enriched in Phosphatidylserine | (György et al., 2011, Baj-Krzyworzeka et al., 2007, Jang et al., 2015) |
Mode of the extracellular release process | Cellular/ constitutive activation | Cellular/ constitutive activation | Cellular/ constitutive activation | (Al-Nedawi et al., 2009) |
Markers | Selectin, flittilin-2, metalloprotease surface phosphatidylserine, glycophorin, Integrin (B1), MMP, CD34, CD40, CD45 | Rab5a/b, CD63, Alix, CD81, CD82, CD9, HSP70, HSP90, flottlin, GTPasestetraspanins, TSG101, ESCRT, and MHC |
Histones, calnexin, Surface phosphatidylserinehistones, annexin V, C3b, cytochrome C, and TSP | (Al-Nedawi et al., 2009, Mathivanan et al., 2010, Caby et al., 2005, Vojtech et al., 2014, Zlotogorski-Hurvitz et al., 2015) |
Biogenesis | By outward budding of the plasma membrane | Upon fusion of multi-vesicular bodies within endosomal networks | Produced by cells going through apoptosis | (Caby et al., 2005, Yuan et al., 2018, Dixon et al., 2018) |
Abbreviations: TSG101: tumor susceptibility gene 101; ESCRT: The endosomal sorting complexes required for transport; HSP: heat shock protein; miRNA: microRNA; MMP: matrix metalloproteinase;